What is the dosage and administration of glucagon (Glucagon) in cases of severe hypoglycemia or for diagnostic purposes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Glucagon Dosage and Administration for Severe Hypoglycemia and Diagnostic Purposes

For severe hypoglycemia in adults, administer glucagon 1 mg subcutaneously, intramuscularly, or intravenously. For children, the dose is 30 mcg/kg subcutaneously to a maximum of 1 mg. 1, 2

Severe Hypoglycemia Treatment

Adult Dosing

  • Unconscious/unable to take oral glucose: 1 mg glucagon via subcutaneous, intramuscular, or intravenous route 1, 3
  • Blood glucose typically rises within 5-15 minutes after administration 1
  • Newer formulations available:
    • Intranasal glucagon: 3 mg as a single dose (preferred due to ease of administration) 1, 4
    • Prefilled pens/syringes: 0.5 mg or 1 mg doses 1

Pediatric Dosing

  • Standard dose: 30 mcg/kg subcutaneously to maximum of 1 mg 1
  • Lower dose of 10 mcg/kg results in smaller glycemic response but with less nausea 1
  • For children ≥4 years old, intranasal glucagon (3 mg) can be used regardless of weight 4

Administration Considerations

  • Glucagon should be prescribed for all patients at risk of level 2 (<54 mg/dL) or level 3 (severe) hypoglycemia 1
  • Family members, school personnel, caregivers should be trained on administration 1
  • Traditional powder formulations require reconstitution before injection 1
  • Newer ready-to-use formulations (intranasal, prefilled pens) are preferred due to faster administration and ease of use 1, 4

Diagnostic Uses of Glucagon

Diagnostic Testing Dosage

  • 1 mg via intramuscular or intravenous route 3
  • Used in various diagnostic procedures including:
    • Radiologic examinations of the stomach, duodenum, small bowel
    • Assessment of beta cell function
    • Provocative testing for growth hormone deficiency

Administration for Diagnostic Purposes

  • Administer as a single 1 mg dose before the procedure 3
  • Available in diagnostic kits containing 1 mg single-dose vial with sterile water for injection 3
  • Timing of administration depends on specific diagnostic procedure

Clinical Considerations

Efficacy

  • Both IV dextrose and glucagon are effective for treating hypoglycemic coma 5
  • Recovery of consciousness is slower with glucagon (6.5 min) compared to IV dextrose (4.0 min) 5
  • Intranasal glucagon has >98% success rate in treating hypoglycemic events 4

Side Effects

  • Common side effects include nausea and vomiting 1, 4
  • Higher doses (standard 1 mg) associated with more gastrointestinal side effects than lower doses 1

Storage and Handling

  • Replace glucagon products when they reach expiration date 1
  • Store according to specific product instructions 1
  • Check insurance coverage as providers may prefer specific glucagon products 1

Hypoglycemia Classification and Treatment Algorithm

Level Blood Glucose Description Treatment
1 <70 mg/dL and ≥54 mg/dL Mild hypoglycemia 15-20g oral glucose
2 <54 mg/dL Moderate hypoglycemia 15-20g oral glucose
3 Any level Severe event with altered mental/physical state requiring assistance Glucagon injection

Special Considerations

  • For conscious patients with hypoglycemia, oral glucose (15-20g) is preferred over glucagon 1, 2
  • Mini-dose glucagon (off-label) can be used for mild or impending hypoglycemia in situations of poor oral intake 6
  • Intranasal glucagon is administered in less than a minute in most scenarios, while IM glucagon takes 1-4 minutes 4
  • Despite its effectiveness, glucagon remains underutilized in clinical practice 7

Remember that glucagon is only effective if the patient has adequate liver glycogen stores. Patients with alcoholism, starvation, or adrenal insufficiency may have limited response to glucagon treatment.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hypoglycemia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon.

Journal of diabetes science and technology, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.